GlassScriptPhysician profile
Cary A Presant
NPI 1538109517
$1,058.88
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $787 · 2020: $199 · 2021: $11.92 · 2022: $38.68 · 2024: $21.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $214.98 | 2019-2020 | |
| Pfizer INC. | $175.16 | 2019-2022 | |
| Janssen Biotech, INC. | $91.41 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $73.55 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $61.23 | 2019 | |
| Incyte Corporation | $60.45 | 2019-2020 | |
| Genentech USA, INC. | $60.18 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $55.58 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $46.07 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $39.03 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.22 | 2019 | |
| Celgene Corporation | $24.29 | 2020 | |
| Janssen Pharmaceuticals, INC | $21.70 | 2024 | |
| Amgen INC. | $20.14 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.49 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $19.45 | 2019 | |
| Daiichi Sankyo INC. | $17.99 | 2019 | |
| Exelixis INC. | $14.04 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cary Presant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.